key: cord-0838388-ovndwepl
authors: Kute, Vivek; Meshram, Hari Shankar; Fleetwood, Vidya A.; Chauhan, Sanshriti; Lentine, Krista L.
title: Solid Organ Transplantation in SARS-CoV-2 Recovered Transplant Candidates: a Comprehensive Review of Recent Literature
date: 2022-03-09
journal: Curr Transplant Rep
DOI: 10.1007/s40472-022-00362-5
sha: 669cd6c61531de40aabd391843396f0b6c818499
doc_id: 838388
cord_uid: ovndwepl

PURPOSE OF REVIEW: As the coronavirus disease 2019 (COVID-19) pandemic continues to surge, determining the safety and timing of proceeding with solid organ transplantation (SOT) in transplant candidates who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and who are otherwise transplant eligible is an important concern. We reviewed the current status of protocols and the outcomes of SOT in SARS-CoV-2 recovered patients. RECENT FINDINGS: We identified 44 published reports up through 7 September 2021, comprising 183 SOT [kidney = 115; lung = 27; liver = 36; heart = 3; simultaneous pancreas-kidney (SPK) = 1, small bowel = 1] transplants in SARS-CoV-2 recovered patients. The majority of these were living donor transplants. A positive SARS-CoV-2 antibody test, although not obligatory in most reports, was a useful tool to strengthen the decision to proceed with transplant. Two consecutive real-time polymerase chain test (RT-PCR) negative tests was one of the main prerequisites for transplant in many reports. However, some reports suggest that life-saving transplantation can proceed in select circumstances without waiting for a negative RT-PCR. In general, the standard immunosuppression regimen was not changed. SUMMARY: In select cases, SOT in COVID-19 recovered patients appears successful in short-term follow-up. Emergency SOT can be performed with active SARS-CoV-2 infection in some cases. In general, continuing standard immunosuppression regimen may be reasonable, except in cases of inadvertent transplantation with active SARS-CoV-2. Available reports are predominantly in kidney transplant recipients, and more data for other organ transplants are needed.

The coronavirus disease (COVID-19) pandemic has posed major challenges to the practice of transplantation worldwide [1•, 2]. The pandemic brought transplant activities to a standstill in different regions of the world, as per the regional COVID-19 toll and available resources [3] . The resumption of transplantation activities occurred in a staged and stepwise process with interruptions by COVID-19 waves [4] . However, there were efforts by many transplant teams to explore strategies for safely resuming transplantation activities within the initial phase of the pandemic.

Globally, as of 6 September 2021, there have been 220,563,227 confirmed cases of COVID-19 reported to the World Health Organization [5] . Such mammoth numbers are a matter of focus and concern for transplant teams, as it leads to a high numbers of COVID-19 recovered patients requiring organ transplant as well as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure prevalence among organ donors. We recently reviewed use of organs from SARS-CoV-2 infected donors after recovery from SARS-CoV-2 [6] . From the candidate perspective, a daunting question has arisen: how and when is it safe to proceed to transplant after infection? The answer to this is still not fully known and requires further review of the evidence.

An international registry study reported high rates of complications in general surgery patients with perioperative COVID-19 [7] . However, there are fewer such reports in the context of SOT. Notably, SOT recipients who contract COVID-19 in the early post-transplant period face an increased risk of adverse outcomes, suggesting that transplanting a patient with active or recently resolved COVID-19 may carry a higher rate of complications [8] [9] [10] . Hence, the decision to proceed with transplant after recent COVID-19 is a complex issue.

To advance understanding of this timely topic, we reviewed the available published evidence on SOT performed in patients who have recovered from COVID-19. We extracted information on eligibility criteria, testing protocols, and clinical outcome in this context.

A total of 115 kidney transplants in patients who have recovered from COVID have been reported. The first case of living donor kidney transplantation (LDKT) where both donor and recipient recovered from COVID-19 illness was reported in Turkey in February 2021 [11] . Over followup of 45 days, the authors reported no complications in the donor-recipient pair. Similar case reports followed from different areas of the world [12] . But the most comprehensive insight into this topic was documented in an Indian study that reported 75 LDKT in recipients who had recovered from COVID-19 [13 •] . The clinical protocol in this series mandated at least two consecutive negative RT-PCR reports, an asymptomatic period of 28 days, and a normal chest x-ray before transplant. The median waiting time from COVID-19 diagnosis until transplant was approximately 60 days in this report. A notable aspect of this cohort was that none of the patients had required mechanical ventilation during COVID-19 [14••] . However, the reported post-transplant follow-up was short, limiting assessment of long-term data. The same authors had previously reported 9 COVID-19 recovered donorrecipient pairs, with similar outcomes and follow-up [13•] . More detailed data for deceased donor kidney transplantation (DDKT) in COVID-19 recovered candidates came from a US report of 13 cases [15••] , in which four patients had moderate to severe COVID-19, of which one required mechanical ventilation. Median waiting time post-COVID-19 was 71 days, and postoperative course for these patients at 3 months follow-up was reported to be uneventful (Table 1) .

At some centers, transplant physicians have gradually shortened the waiting time from COVID-19 recovery to transplantation, and there are reports of transplants performed in candidates who were still COVID-19 positive. In an Italian report, DDKT was performed in a candidate with recovered COVID-19 at 29 days after the first negative PCR, a significantly shorter waiting time than the previously described median 60-71 days [16] . Some transplants have been performed in patients with active COVID-19: there are five reports of kidney transplants in candidates with positive RT-PCRs, including those with high cycle threshold (CT) values [17, 18] as well as those with neutralizing antibodies [19] . Additionally, successful simultaneous pancreaskidney transplant (SPK) after COVID-19 recovery has been reported [20] . The majority of the published data about LDKT in COVID-19 recovered patients is from developing nations, while DDKT reports predominate in developed countries, likely attributable to the fact that deceased donation is still in its infancy in the developing world; however, safety profiles appear similar for both.

A European study recently studied antibody response in hemodialysis patients and found the immune response varied with the severity of infection. They also reported a low level of seroresponse and waning of antibody response in followup [21] . These data demonstrate that transplant candidates with previous COVID-19 are at theoretically more risk for re-infection or reactivation even after transplantation. 

There are reports of successful extracorporeal membrane oxygenation (ECMO) use as salvage therapy in severe COVID-19 [22, 23] . But there are also considerable numbers of COVID-19 cases who fail ECMO and are potential candidates for lung transplantation (LT). The first case series of LT in a SARS-CoV-2 recovered patient was reported in a US study, where 3 patients suffering from irreversible lung injury benefited from LT [24] . There are also a few reports of successful LT in other nations [25] [26] [27] [28] . In general, conducting a LT in a recipient after recovered SARS-CoV-2 infection is relatively difficult compared to other SOT. The logistics involved in a successful LT can be inferred from a report where a candidate with COVID-19 was transferred from Mexico to Korea for LT [29] . Some insight into the status of LT after recovery from SARS-CoV-2 comes from a recently published multi-institutional series of 12 cases [30••] . The authors proposed criteria for LT in COVID-19 patients with endorgan lung damage, suggesting that this procedure should be reserved for those aged < 65 years, and with approximately 4-6 weeks of irreversible lung injury. They also suggested two negative lower respiratory tract fluid RT-PCRs, and early weaning of sedation in the post-transplant period to promote early recovery. They also favored double lung transplantation, as the majority of their cohort had superimposed pulmonary hypertension. In follow-up, the outcomes of LT in patients recovered from COVID have been encouraging [31] . Another complex procedure is a heart transplant in a COVID-19 recovered patient. The first such case was performed in the USA [32] . In another report, a heart retransplantation was performed in a patient in the recovery phase of COVID-19 with an RT-PCR positive report. The outcome was good but the patient remained SARS-CoV-2 positive until day 44 of follow-up [33] . There is also a report of emergency heart transplantation in a patient who developed fulminant myocarditis related to COVID-19 [34] .

The first and largest cohort of living donor liver transplantation (LDLT) COVID-19 recovered patients was described in an Indian study [35••] . A US study described the first and largest series of deceased donor liver transplantation (DDLT) in COVID-19 recovered patients [36••] . There are also case reports from different parts of the world [37] [38] [39] . There has not been consensus on a specific waiting time before transplant, but 4 weeks seems justified. However, many reports describe proceeding to transplantation with no waiting time as transplant was judged to be a life-saving procedure. Liver transplantation has also been offered to COVID-19 recovered recipients with other complicating factors, such as HIV [40] and very young age (Table 2 ) [41] .

Similar to kidney transplantation, the need for an interval from COVID-19 clearance has been challenged. In Italy, a DDLT was performed in as early as 9 days after being diagnosed with asymptomatic COVID-19 and just 2 days after a negative RT-PCR; the outcome was uneventful [42] . In another Italian report, a decision to perform an emergency DDLT was made, using a COVID-19 positive donor. The recipient was RT-PCR positive but had neutralizing antibodies [42] . In the USA, an emergency DDLT was performed in an RT-PCR positive critical COVID-19 patient. The decision to proceed was taken in view of his deteriorating liver illness and high CT values despite having no antibody response [43] . In the USA, an urgent DDLT was performed successfully in a patient who had COVID-19 illness for 2 months and was persistently RT-PCR positive at the time of transplant [44] . In general, there have been no obvious COVID-19 related complications in the follow-up of these cases. However, there are reports of portal venous thrombosis and hepatic artery thrombosis in two DDLT transplanted to COVID-19 recovered patients [45, 46] . Although the association of this complication with COVID-19 is not clearly delineated, it raises a word of caution. There are very few reports of reactivation or re-infection with COVID-19 following SOT in recovered patients. One such report demonstrated repeated positive viral loads till 1 month of successful DDLT. However, the patient remained asymptomatic throughout [47] . Post-COVID-19 cholangiopathy emerged as a new cause of chronic liver disease requiring transplantation in this pandemic [48, 49] , but has not yet been reported as a complication of liver transplantation to COVID-19 positive recipients.

It is difficult to delineate any uniform guidelines for assessing eligibility for transplant in COVID-19 recovered patients. Various international bodies have come up with a consensus for surgeries in recovered patients. The American Society of Anesthesiologists and Anesthesia Patient Safety Foundation Joint Statement on elective surgery, published on 8 December 2020, recommended 4 weeks waiting time for asymptomatic or mild cases; 6 weeks for hospitalized patients; 8-10 weeks for patients hospitalized with comorbid conditions; and 12 weeks for severe cases [50] . The International Society of Heart and Lung Transplantation guidelines revised on 1 February 2021 recommended at least 1 negative RT-PCR with normal chest imaging along with no symptoms and waiting time of at least 14 days for asymptomatic, and 21 days for symptomatic COVID-19 cases [51] . If RT-PCR remains positive beyond 21 days of illness in a recovered candidate, the patient can still proceed for transplant. Recently, the Indian Society of Organ Transplant guidelines for SOT from recovered donors and recipients recommended at least 2 negative RT-PCR, with an asymptomatic period of 28 days and normal chest radiology before [52] .

There are a few studies that have proceeded with one RT-PCR negative report, while some have more than 3 negative reports. From the available evidence, it is justified to document at least two negative RT-PCR reports, to eliminate the possibility of a false negative. The other salient criterion is that the patient must be asymptomatic after recovery. The optimal symptom-free duration before transplant is not known, but recovery for more than 1 month seems safe before an elective transplant. Nevertheless, there are reports of life-saving transplantation in extremely ill patients as well. As clinical practice and understanding have evolved with time in this pandemic, the threshold for proceeding to a transplant has become less strict. In the current era, there are no data to indicate that a particular waiting time is ideal for proceeding with SOT; this decision should be based solely on the urgency of transplant [53] . There is emerging evidence to support transplant from RT-PCR positive patients in some circumstances. The rationale behind proceeding for transplant here is the high lag time for a negative RT-PCR report in chronic conditions like chronic kidney disease. The studies which successfully transplanted such case were buttressed by a report of protective antibody level in many cases. There are multiple studies which show that a low cycle threshold of RT-PCR is associated with high viral loads; hence, candidates with persistently positive RT-PCRs but with high CT values, if asymptomatic, could be considered for proceeding to transplant based on the urgency of the procedure [54, 55] . Low CT values in RT-PCR are associated with the growth of COVID-19 in cultures with high viral loads, so it would be safest to avoid transplanting patients with low CT values [56] . If the candidate is in the second week of illness, then the chances of lesser viral loads are higher [57] . A recent meta-analysis in the general population showed the incidence of RT-PCR positivity as 14.7% between day 41 and day 60 post-discharge [58] . Another meta-analysis showed a 12% incidence of recurrent RT-PCR positivity in post-discharge recovered patients in the general population [59] . The above two studies imply that the fluctuations in RT-PCR between negative and positive after recovery can affect the timing of transplant, so again RT-PCR should not be the sole consideration in a decision about the timing of a transplant (Table 3) .

While most reports required normal chest imaging before transplant, owing to high likelihood of residual radiographic changes for months following infection, we suggest the transplant should proceed even in cases of underlying residual damage. There is a report of an ABO kidney transplant where the team waited for inflammatory markers to resolve despite being RT-PCR negative and asymptomatic [60] . However, normalization of inflammatory markers before transplant should not be a mandatory prerequisite. There is an interesting report of four kidney transplantation where the candidates had no symptoms and their RT-PCRs came back positive retrospectively [61] . Interestingly, all recipients did well and remained asymptomatic, except for acute cellular rejection in two cases, which may be attributable to reduction of IS post-operatively out of concern for a possible flare of COVID-19.

The limitation of this review is that there are only two cases of heart transplants and one case of SPK in a recovered patient. Hence, our review cannot provide much information about these organs. Future reports with these organs and prospective studies from international registries will throw more light on this topic.

The sensitivity of RT-PCR approximates 70%, so there will be high chances of false-negative reports [62] . A validated better test in the future will be more helpful. At this point, it is prudent to be on the safe side, with repeated RT-PCR assessments in non-emergency transplants.

The follow-up in most reports was short, and longer follow-up data in these transplant recipients will provide important information regarding safety and outcomes.

In an additional note, there is a report of a 9-year-old female with short bowel syndrome 3 months of post-COVID-19, which required a small bowel transplant [63] . This indicates that COVID may be part of the transplant world in ways we have not yet anticipated.

In summary, transplantation from SARS-CoV-2 recovered patients has been reported to be safe with good short-term outcomes in multiple case reports and case series, although kidney transplantation is predominant in these reports. The optimal criteria to proceed with transplant should include evidence of a lack of viral replication. Emerging data suggest that a negative RT-PCR report should not be mandatory Table 2 Liver transplantation in candidates with recovered or positive SARS-CoV-2 infection. COVID-19 severity was defined as mild in those with only upper respiratory symptoms, moderate when requiring low flow oxygen, and severe in cases with higher oxygen requirement. * = Cases which were RT-PCR positive at the time of transplant surgery. in all cases to proceed with transplantation. Alteration of early post-transplant immunosuppression in this context does not appear to be necessary, as per the available data. Nevertheless, in cases of life-saving or inadvertent transplantation with active SARS-CoV-2, modifications in the immmunosuppressive regimen are justified. There is also a need to gather further information for transplantation of organs such as the lung, pancreas, and intestine, where data are relatively scant. This review of data from available reports through September 2021 may serve as a foundation for decision-making in the challenging approach to transplantation for SARS-CoV-2 recovered patients. Hopefully, the vaccination era will bring a steep decline in these challenging clinical scenarios [64, 65] .

Author Contribution All have made equal contributions in the manuscript.

Funding K.L.L. is supported by the Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant R01DK120551.

Data Availability Not applicable.

Code Availability Not applicable.

Ethics Approval Not required.

The authors declare no competing financial interests. K.L.L. is a volunteer member of the American Society of Nephrology (ASN) COVID-19 Response Team.

Informed Consent Not applicable. 

Early impact of COVID-19 on transplant center practices and policies in the United States

Expedited SARS-CoV-2 screening of donors and recipients supports continued solid organ transplantation

/? gclid= EAIaI QobCh MIpMn Ik-K08QI VSx0r Ch0K0 Q8qEA AYASA BEgLa JfD_ BwE. Last accessed on 6

Use of organs from SARS-CoV-2 infected donors: is it safe? A contemporary review

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study [published correction appears in Lancet

Early COVID-19 infection after lung transplantation

COVID-19 infection in solid organ transplant recipients: a single-center experience with patients immediately after transplantation

Liver transplant recipients infected with SARS-CoV-2 in the early postoperative period: lessons from a single center in the epicenter of the pandemic

The first kidney transplantation after recipient and living donor recovered from COVID-19

ABO incompatible kidney transplant after recovery from severe COVID-19 pneumonia

Is it safe to be transplanted from living donors who recovered from COVID-19? Experience of 31 kidney transplants in a multicenter cohort study from India

A multicenter cohort study from India of 75 kidney transplants in recipients recovered after COVID-19

This reference describes the largest cohort of deceased donor kidney transplantation with prior COVID-19 in candidates

Successful kidney transplantation after COVID-19

Kidney transplantation in a COVID-19-positive pediatric recipient

Repeat SARS-CoV-2 testing after recovery Is a pretransplant PCR necessary?

Kidney transplantation from a SARS-CoV-2-positive donor for the recipients with immunity after COVID-19

Successful simultaneous pancreas and kidney transplant in a patient post-COVID-19 infection

Rapid decline of anti-SARS-CoV-2 antibodies in patients on haemodialysis: the COVID-FRIAT study

Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study

Lung transplantation for patients with severe COVID-19

Lung transplantation as a therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis

Lung transplantation for elderly patients with end-stage COVID-19 pneumonia

Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient

How I do it: considering lung transplantation for patients with COVID-19

Experience of international air transportation and subsequent lung transplant in a patient with COVID-19-associated acute respiratory distress syndrome: a case report

Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries

Emergency lung transplantation after COVID-19: immunopathological insights on two affected patients

Successful heart transplantation in a patient who recovered from COVID-19

Heart retransplantation following COVID-19 illness in a heart transplant recipient

Successful heart transplantation for COVID-19-associated post-infectious fulminant myocarditis

Early liver transplantation after COVID-19 infection: the first report

When is it safe to perform abdominal transplantation in patients with prior SARS-CoV-2 infection: a case series

This reference describes the largest cohort of deceased donor liver transplant of COVID-19 recovered candidates

Successful liver transplantation in a patient recovered from COVID-19

Successful liver transplantation immediately after recovery from COVID-19 in a highly endemic area

Orthotopic liver transplantation in a cirrhotic patient with recent COVID-19 infection

Liver transplantation in a patient with human immunodeficiency virus and coronavirus disease

Liver transplant in a recently COVID-19 positive child with hepatoblastoma

Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor

Liver transplantation for acute liver failure in a SARS-CoV-2 PCR-positive patient

Successful orthotopic liver transplantation in a patient with a positive SARS-CoV2 test and acute liver failure secondary to acetaminophen overdose

A challenging liver transplantation for decompensated alcoholic liver disease after recovery from SARS-CoV-2 infection

Recurrent hepatic artery thrombosis following living donor liver transplant as sequelae of SARS-CoV-2 infection: case report

Liver transplantation in a patient after COVID-19 -rapid loss of antibodies and prolonged viral RNA shedding

Post-Covid-19 cholangiopathy-a new indication for liver transplantation: a case report

Cholangiopathy after severe COVID-19: clinical features and prognostic implications

Statement on Elective Surgery and Anesthesia for Patients after COVID-19 Infection

SARS-CoV-2_-Guida nce-for-Cardi othor acic-Trans plant-and-VADcente rs

ISOT consensus statement for the kidney transplant recipient and living donor with a previous diagnosis of COVID 19

COVID-19 and liver transplantation

A systematic review of the clinical utility of cycle threshold values in the context of COVID-19

Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples

Repeat COVID-19 molecular testing: correlation of SARS-CoV-2 culture with molecular assays and cycle thresholds

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients

SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis

ABO incompatible kidney transplant after recovery from severe COVID-19 pneumonia

Kidney transplantation in patients with SARS-CoV-2 infection: a case series report

Retest positive for SARS-CoV-2 RNA of "recovered" patients with COVID-19: persistence, sampling issues, or re-infection

Pediatric living donor intestine transplant following an atypical complication of COVID-19: a unique case report from India

Practicing With Uncertainty: Kidney Transplantation During the COVID-19

Survey of current transplant center practices regarding COVID-19 vaccine mandates in the United States

Successful kidney transplantation after COVID-19 infection in two cases

Successful deceased donor kidney transplantation to a recipient with a history of COVID-19 treatment

Successful Kidney transplantation after recovery from COVID -19

SARS-CoV-2 infection on the kidney transplant waiting list: can a patient be transplanted after COVID-19?

Infección por SARS-CoV-2 en lista de espera de trasplante renal: ¿se puede trasplantar un paciente con antecedente de COVID-19?

Renal transplantation after recovery from COVID-19 -a case report with implications for transplant programs in the face of the ongoing corona-pandemic

Urgent liver transplantation soon after recovery from COVID-19 in a patient with decompensated liver cirrhosis

Lung transplantation in COVID 19 ARDS -short term outcomes